Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
May 02 2024 - 4:30AM
Planegg/Martinsried, May 2, 2024.
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard),
an immuno-oncology platform company focusing on the discovery and
development of T cell immunotherapies for solid tumors, announces
today that the Company has been issued a patent by the European
Patent Office protecting its T cell receptor (TCR) targeting
NY-ESO-1 (New York esophageal squamous cell carcinoma 1), a
well-recognized and validated cancer-testis antigen, which is
expressed in multiple tumor types.
“We are delighted to announce the protection of
our NY-ESO-1-targeted TCR in Europe. This TCR, together with the
PD1-41BB costimulatory switch protein (CSP), serves as the main
component of our lead program MDG1015. This patent grant adds to
similar patents that were also granted in the United States, Japan,
South Korea, Taiwan and Australia and reinforces the key
technologies of our End-to-End Technology platform and its ability
to generate optimal affinity 3S (sensitive, specific and safe)
TCRs,“ said Selwyn Ho, CEO at Medigene AG. “Along with our
differentiated TCR-T therapies for solid tumors, such as MDG1015,
we are also exploring opportunities to expand the application of
our potential best-in-class TCRs into other modalities such as T
cell engagers (TCE) and TCR natural killer cell (TCR-NK)
therapies.”
Medigene continually extends and strengthens its
patent portfolio with new technologies and expands existing patents
into additional jurisdictions. The Company maintains over 20
different patent families worldwide covering applications
protecting Medigene’s 3S TCRs as well as its exclusive E2E Platform
technologies.
--- end of press release ---
About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology
platform company dedicated to developing differentiated T cell
therapies for treatment of solid tumors. Its End-to-End Platform is
built on multiple proprietary and exclusive technologies that
enable the Company to generate optimal T cell receptors against
both cancer testis antigens and neoantigens, armor and enhance
these T cell receptor engineered (TCR) -T cells to create
best-in-class, differentiated TCR-T therapies, and optimize the
drug product composition for safety, efficacy and durability. The
End-to-End Platform provides product candidates for both its own
therapeutics pipeline and partnering. Medigene’s lead TCR-T program
MDG1015 is expected to receive IND/CTA approval in the second half
of 2024. For more information, please visit
https://medigene.com/
About Medigene’s MDG1015 Program
MDG1015 is a first-in-class, 3rd generation T
cell receptor engineered T cell (TCR-T) therapy targeting NY-ESO-1/
LAGE-1a, a well-recognized and validated cancer testis antigen,
which is expressed in multiple tumor types. MDG1015 contains our
optimal affinity 3S (sensitive, specific and safe) NY-ESO-1/LAGE-1a
TCR combined with our proprietary PD1-41BB costimulatory switch
protein that blocks the PD1/PD-L1 inhibitory axis while
simultaneously activating the T cell through the well described
-41BB pathway further enhancing the activity and persistence of the
TCR-T in the hostile tumor microenvironment. The Company expects
IND/CTA approval for MDG1015 in the second half of 2024.
This press release contains forward-looking
statements representing the opinion of Medigene as of the date of
this release. The actual results achieved by Medigene may differ
significantly from the forward-looking statements made herein.
Medigene is not bound to update any of these forward-looking
statements. Medigene® is a registered trademark of Medigene AG.
This trademark may be owned or licensed in select locations
only.
Medigene AG
Pamela Keck Phone: +49 89 2000 3333 01 E-mail:
investor@medigene.com
In case you no longer wish to receive any
information about Medigene, please inform us by e-mail
(investor@medigene.com). We will then delete your address from our
distribution list.